MiMedx Group, Inc $MDXG Shares Bought by First Trust Advisors LP

First Trust Advisors LP lifted its holdings in MiMedx Group, Inc (NASDAQ:MDXG) by 50.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 553,320 shares of the company’s stock after purchasing an additional 184,439 shares during the quarter. First Trust Advisors LP owned 0.37% of MiMedx Group worth $2,186,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Royal Bank of Canada lifted its holdings in MiMedx Group by 1.4% in the first quarter. Royal Bank of Canada now owns 982,532 shares of the company’s stock worth $7,466,000 after purchasing an additional 13,629 shares during the period. AQR Capital Management LLC grew its position in MiMedx Group by 42.6% in the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock valued at $109,000 after buying an additional 4,296 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in MiMedx Group during the 1st quarter valued at about $232,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in MiMedx Group by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock valued at $559,000 after buying an additional 4,049 shares during the period. Finally, Millennium Management LLC increased its stake in MiMedx Group by 93.9% during the 1st quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock valued at $9,355,000 after buying an additional 596,016 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on MDXG. Citizens Jmp reduced their price target on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research note on Thursday, April 30th. Weiss Ratings lowered shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 18th. Wall Street Zen cut MiMedx Group from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. Finally, Craig Hallum dropped their target price on MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, MiMedx Group currently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

MiMedx Group Trading Up 3.8%

Shares of MDXG stock opened at $4.34 on Friday. The stock has a 50-day simple moving average of $3.98 and a 200 day simple moving average of $4.19. The stock has a market capitalization of $632.60 million, a P/E ratio of 108.53 and a beta of 1.45. MiMedx Group, Inc has a fifty-two week low of $3.03 and a fifty-two week high of $7.97. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. The firm had revenue of $64.36 million for the quarter, compared to analysts’ expectations of $63.46 million. On average, sell-side analysts expect that MiMedx Group, Inc will post -0.1 earnings per share for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.